AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31044235
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg moxidectin
Trial: 31044235
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg moxidectin
Trial: 31044235
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg moxidectin plus 400 mg albendazole
Trial: 31044235
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg moxidectin plus 400 mg albendazole
Trial: 31044235
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg moxidectin plus 400 mg albendazole
Trial: 24149557
Drug: Dance exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance exercise (twice a week for 6 months)
Trial: 19349290
Drug: Broccoli sprouts
RxNorm normalized name: broccoli sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli sprouts (70 g/d; containing 420 micromol of SF precursor) for 8 weeks
Trial: 15204158
Drug: Acitretin 25-50
RxNorm normalized name: acitretin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin 25-50 mg/day for 1 month
Trial: 15204158
Drug: Conventional topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional topical treatment (betamethasone/salicylic acid ointment)
Trial: 9839766
Drug: Donepezil HCl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil HCl (10 mg day(-1)) administered for 19 consecutive days with a single dose of warfarin (25 mg) on day 14.
Trial: 9839766
Drug: Warfarin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (25 mg) administered alone on day 14 after an initial 13-day period with no medication.
Trial: 9839766
Drug: Donepezil HCl
RxNorm normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil HCl (10 mg day(-1)) administered for 19 days with an additional single dose of warfarin (25 mg) on day 41 after a washout period.
Trial: 7648286
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with 2 mg Photofrin/kg and 120 J/cm2 laser light (n = 5)
Trial: 7648286
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with 2 mg Photofrin/kg and 70 J/cm2 laser light (n = 4)
Trial: 7648286
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with 2 mg Photofrin/kg
Trial: 70947
Drug: Oxatimide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatimide (20 mg, two tablets three times a day for 2 weeks)
Trial: 26190853
Drug: Four positions
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four positions for intratracheal beractant administration (Group I)
Trial: 26190853
Drug: Two positions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two positions for intratracheal beractant administration (Group II)
Trial: 26190853
Drug: Neutral position
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral position for intratracheal beractant administration (Group III)
Trial: 22357901
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of controlled-release oxycodone (CRO)
Trial: 22357901
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of controlled-release oxycodone (CRO)
Trial: 20075530
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (1 microg/kg)
Trial: 12490344
Drug: Topiramate (300-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (300-400 mg/day)
Trial: 28725257
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no relaxation therapy)
Trial: 2144018
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion floxuridine (FUDR) at 0.15 mg/kg/d (IV) or 0.25 mg/kg/d (IA) for 14 days at monthly intervals.
Trial: 7316249
Drug: Environmental Control
RxNorm normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Environmental Control Unit (ECU) treatment, where patients were taken off all medication and not fed until leg pain and swelling disappeared (4 to 7 days).
Trial: 7316249
Drug: Environmental Control
RxNorm normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Environmental Control Unit (ECU) treatment with daily exercycle at 150 kpm for one mile to demonstrate absence of phlebitis.
Trial: 7316249
Drug: Standard anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anticoagulant regime, bed rest, and support hose (control group).
Trial: 7316249
Drug: Environmental Control
RxNorm normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Environmental Control Unit (ECU) treatment.
Trial: 31230466
Drug: Standard clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinical treatment (control group)
Trial: 16368055
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg/day
Trial: 9549743
Drug: Metoclopramide (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (0.25 mg.kg-1)
Trial: 7618677
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg droperidol added to 120 mg morphine in 60 ml saline
Trial: 6734073
Drug: Glycerol 92
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol 92 mmol/l
Trial: 6734073
Drug: Glycerol 272
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol 272 mmol/l
Trial: 6734073
Drug: Glucose 76
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose 76 mmol/l
Trial: 6734073
Drug: Glucose 215
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose 215 mmol/l
Trial: 31404018
Drug: Imipenem 3
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem 3 × 500 mg intravenously daily
Trial: 26972646
Drug: Cisplatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (30 mg/m²) and Irinotecan (50 mg/m²) on day 1, 8, 22, 29 during 45 Gy radiation therapy (RT), 1.8 Gy per day over 5 weeks.
Trial: 26972646
Drug: Cisplatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (30 mg/m²) and Paclitaxel (50 mg/m²) on day 1, 8, 15, 22, 29 with RT, followed by adjuvant cisplatin (75 mg/m²) and paclitaxel (175 mg/m²) day 1 every 21 days for 3 cycles.
Trial: 16322134
Drug: Modafinil (170-425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (170-425 mg once daily)
Trial: 8390559
Drug: Prophylactic ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic ganciclovir (10 mg/kg/day)
Trial: 8390559
Drug: Therapeutic ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapeutic ganciclovir (10 mg/kg/day)
Trial: 2442558
Drug: Lisinopril (1.25‐10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (1.25‐10.0 mg) administered on days 1 and 3
Trial: 2442558
Drug: Lisinopril (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (oral and intravenous administration)
Trial: 22503720
Drug: Xylazine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine (0.05 mg/kg BW, i.m.)
Trial: 20518174
Drug: Isotritinoin soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotritinoin soft capsule (taken orally)
Trial: 20518174
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (control group 2)
Trial: 12008199
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further loco-regional treatment (watch policy)
Trial: 7819652
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acids (BCAAs) in a carbohydrate solution
Trial: 2891798
Drug: Postoperative RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative RT plus chemotherapy with CAP (Cyclophosphamide, Adriamycin, and Cisplatin) for 6 months
Trial: 2891798
Drug: Postoperative RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative RT plus chemotherapy with CAP
Trial: 19464878
Drug: Ropivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine with sufentanil 0.5 microg/mL
Trial: 19464878
Drug: Levobupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine with sufentanil 0.5 microg/mL
Trial: 16683215
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma levels of ACE (> 50 U/L)
Trial: 16683215
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma levels of PAI-1 (> 43 ng/ml)
Trial: 16683215
Drug: Thrombolytic agents
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agents with high ACE levels
Trial: 9223815
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (800 micrograms/d for 6 weeks)
Trial: 8387067
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy with 50 Gy in 25 daily fractions over 5 weeks
Trial: 8387067
Drug: Cytotoxic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic therapy (cyclophosphamide, methotrexate, and 5-fluorouracil)
Trial: 31590692
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment of Vestibular Rehabilitation (VR) and Cognitive Behaviour Therapy (CBT) with eight sessions after a one-session Brief Intervention Vestibular Rehabilitation (BI-VR)
Trial: 27621048
Drug: Inhaled nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrous oxide with oxygen (N2O/O2) via nasal mask, titrated to a maximum 70%:30% mixture during the procedure, with pre-procedure placebo pills.
Trial: 27621048
Drug: Inhaled O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled O2 during the procedure and 5/325 mg hydrocodone/acetaminophen and 1 mg lorazepam pre-procedure (active control).
Trial: 31626649
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (400 μg)
Trial: 20090338
Drug: 100 U
RxNorm normalized name: vitamin E 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 U BT injection (Group A)
Trial: 20090338
Drug: Balloon dilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon dilation plus 100 U BT injection (Group C)
Trial: 17350629
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg daily of synthetic conjugated estrogens A
Trial: 15188350
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg daily subcutaneous injection)
Trial: 9669057
Drug: Mibefradil 50
RxNorm normalized name: mibefradil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 50 mg once daily
Trial: 9669057
Drug: Mibefradil 150
RxNorm normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mibefradil 150 mg once daily
Trial: 7833222
Drug: Perindoprilat (Pt,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindoprilat (Pt, 0.67 mg)
Trial: 30106528
Drug: Two-step 0.454%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-step 0.454% SnF₂ dentifrice then 3% H₂O₂ whitening gel sequence
Trial: 25486333
Drug: High-dose naringin
RxNorm normalized name: Naringin
DrugBank: Naringin (DB16859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naringin (1050 mg)
Trial: 25486333
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 mg talinolol only)
Trial: 21189384
Drug: HAI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI plus systemic therapy with bevacizumab (Bev)
Trial: 21189384
Drug: HAI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI plus systemic therapy without bevacizumab (no Bev)
Trial: 18285602
Drug: Breast intensity-modulated
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast intensity-modulated radiation therapy (IMRT)
Trial: 16571277
Drug: SSLA 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSLA 200 mg in 250 ml of 5% glucose solution for intravenous dripping daily (test group A)
Trial: 16571277
Drug: SSLA 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSLA 400 mg in 250 ml of 5% glucose solution for intravenous dripping daily (test group B)
Trial: 16571277
Drug: DSI 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSI 20 ml daily (control group)
Trial: 15072499
Drug: Newer approaches
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer approaches to the management of penile cancer including laser, photodynamic therapy, neoadjuvant therapy, and sentinel node mapping by lympho‐gamma‐scintigraphy.
Trial: 10949722
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and non-steroidal anti-inflammatory drugs as needed
Trial: 10700536
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (Group I)
Trial: 30979026
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of data from both studies
Trial: 27619174
Drug: Web-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based intervention with daily text-messaging (WB + M)
Trial: 17388708
Drug: Atomoxetine (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (40-120 mg/day)
Trial: 19421788
Drug: Acetaminophen (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (750 mg PO every 6 hours)
Trial: 15446778
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg once daily)
Trial: 9696467
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of morphine (group A)
Trial: 31833000
Drug: CAMBIA® 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMBIA® 50 mg
Trial: 31833000
Drug: IM ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM ketorolac 60 mg
Trial: 27918382
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion of meropenem (4 hours)
Trial: 27918382
Drug: Conventional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional infusion of meropenem (30 minutes)
Trial: 27918382
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion of meropenem
Trial: 21488053
Drug: Caffeine (CAFF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAFF) 6 mg kg(‐1)
Trial: 19581850
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg 90 minutes before surgery)
Trial: 12098150
Drug: Liquid silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid silicone injections (6 injections of 0.2mL)
Trial: 7594097
Drug: Recombinant hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hirudin (dosage group I: 0.3 mg/kg body weight bolus, 0.12 mg/kg per h for 24 h)
Trial: 7594097
Drug: Recombinant hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hirudin (dosage group II: 0.5 mg/kg bolus, 0.24 mg/kg per h for 24 h)
Trial: 7594097
Drug: Heparin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (150 IU/kg bolus, 20 IU/kg per h for 24 h)
Trial: 7594097
Drug: Recombinant hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hirudin (dosage group I)
Trial: 7594097
Drug: Recombinant hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hirudin (dosage group II)
Trial: 2105792
Drug: Immunoscintigraphy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoscintigraphy with myosin antibody
Trial: 2105792
Drug: Wall motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wall motion assessment at the site of antibody uptake
Trial: 2164477
Drug: Propranolol (non-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (non-selective beta-blocker)
Trial: 6108035
Drug: Metoprolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (beta 1-selective drug)
Trial: 6108035
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Propranolol, Metoprolol)
Trial: 28009680
Drug: Nonthermal focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonthermal focused ultrasound treatment (3 treatments at 2-week intervals)
Trial: 28009680
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase (4-week before treatment)
Trial: 28009680
Drug: Nonthermal focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonthermal focused ultrasound treatment
Trial: 25671826
Drug: LAM add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM add-on combination therapy (100 mg LAM and 10 mg ADV per day)
Trial: 25671826
Drug: ETV monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETV monotherapy (0.5 mg ETV per day)
Trial: 17722824
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment for 30 days
Trial: 17722824
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral Gliguidon or subcutaneous insulin)
Trial: 15019802
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral DHEA daily for 4 weeks
Trial: 11811112
Drug: Galstena treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galstena treatment
Trial: 10215731
Drug: Ranitidine 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 125 mg
Trial: 28815789
Drug: ED-initiated buprenorphine
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED-initiated buprenorphine treatment
Trial: 28815789
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to community-based treatment
Trial: 29402628
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anesthesia (TIVA) with propofol
Trial: 18176118
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of erlotinib under fed conditions
Trial: 18176118
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of erlotinib under fasting conditions
Trial: 18176118
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of erlotinib daily for 8 days under feeding on day 8 after 7 days of fasting
Trial: 18176118
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of erlotinib daily for 8 days under fasting on day 8 after 7 days of feeding
Trial: 10203002
Drug: L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1 g intravenous dose)
Trial: 2018901
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic solution injected at body temperature
Trial: 2018901
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic solution injected at room temperature
Trial: 31750800
Drug: Light-cured tetracaine-based
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Light-cured tetracaine-based anesthetic gel